Managed entry: Difference between revisions
Editor iHTS (talk | contribs) (Created page with "''<small><sup>23</sup>Klemp M, Frønsdal KB, Facey K. What principles should govern the use of managed entry agreements? Int J Technol Assess Health Care. 2011 Jan;27(1):77-83.</small>'' A conditional arrangement between manufacturer and payer that enables earlier reimbursement of a health technology to address uncertainty in its performance or to manage its utilization. '''Note 1:''' Related terms include managed entry agreement, managed entry scheme, coverage with e...") |
Editor iHTS (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
'''Note 1:''' Related terms include managed entry agreement, managed entry scheme, coverage with evidence development, and managed access. | A conditional arrangement between manufacturer and payer that enables earlier reimbursement of a [[health technology]] to address uncertainty in its performance or to manage its utilization. | ||
'''Note 1:''' Related terms include managed entry agreement, managed entry scheme, [[coverage with evidence development]], and managed access. | |||
[http://htaglossary.net/managed-entry] | [http://htaglossary.net/managed-entry] | ||
Revision as of 12:32, 9 November 2023
23Klemp M, Frønsdal KB, Facey K. What principles should govern the use of managed entry agreements? Int J Technol Assess Health Care. 2011 Jan;27(1):77-83.
A conditional arrangement between manufacturer and payer that enables earlier reimbursement of a health technology to address uncertainty in its performance or to manage its utilization.
Note 1: Related terms include managed entry agreement, managed entry scheme, coverage with evidence development, and managed access.